Small molecule inhibitors of pr3 and hne and uses thereof
AssigneeOrixa Therapeutics LLC
InventorsAdam Seth HAEBERLE, Matteo PANZA, James Bernard KRAMER, Zahra ASSAR-NOSSONI, Matt SIMON
Life of this patent
Estimating the term…
Abstract
Disclosed herein are novel small molecules that can be used therapeutically to treat ailments and diseases associated with an over-active or undesired immune response. Specific embodiments include inhibitors of Proteinase 3 (PR3) and Human Neutrophil Elastase (HNE) and methods for their synthesis and use. The agents can be used to treat alpha-1 antitrypsin deficiency and other ailments related to neutrophil activity.
Claims25
A compound of Formula DCT5A or an analog thereof:
-7. (canceled)
-20. (canceled)
A method of inhibiting the activity of Proteinase 3 (PR3) and/or Human Neutrophil Elastase (HNE) in a subject in need thereof, the method comprising administering an effective amount of a compound selected from DCT-5A, DCT-5B, DCT-5C, MP-77, MP77B and MP-77C:
A compound of formula JK-58, JK-53, JK-169, JK-178, PEH-126, PEH-109, JK-205, PEH-129, PEH-111, KO-4, JK-187, JK-123, MP-76, JK-78, JK146, JK-145, JK121, JK138, JK141, JK-76, MP-46, JK-99, JK-87, JK-25, JK-1, PEH-70, DCT-1, DCT-8, DCT-7, MP-48, PEH-73, PEH-101, PEH-100, PEH-98, PEH-81, DCT-10, DCT-3 or DCT-6, a pharmaceutical salt, analog or pro-drug thereof:
(canceled)
(canceled)
Dependencies are inferred from the claim text.